Impact of GM-CSF and two-site vaccination on clinical outcomes after multipeptide vaccination for melanoma: long-term analysis of a randomized phase II trial

These results challenge the use of GM-CSF as a local vaccine adjuvant and support two-site vaccination. Future work to characterize the locoregional immune response to cancer vaccination at the injection site and vaccine-draining lymph nodes is warranted.